Guggenheim Reiterates Buy on Assembly Biosciences, Maintains $43 Price Target

Benzinga Newsdesk www.benzinga.com Neutral 90.2%

Neg 0% Neu 90.2% Pos 0%

Guggenheim analyst Vamil Divan reiterates Assembly Biosciences (NASDAQ:ASMB) with a Buy and maintains $43 price target.

Comments

No comments yet. Be the first!